Материал: 10 Фибрилляция предсердий

56.Hindricks G., Pokushalov E., Urban L., et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation – results of the XPECT trial. Circ Arrhythm Electrophysiol 2010; 3: 141–147.

57.Dorian P., Guerra P. G., Kerr C. R., et al. Validation of a new simple scale to measure symptoms in atrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale. Circ Arrhythm Electrophysiol 2009; 2: 218–224.

58.Klein A. L., Grimm R. A., Murray R. D., et al. Stoddard MF. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344: 1411–1420.

59.Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388–2442.

60.Haverkamp W., Breithardt G., Camm A. J., et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000; 21: 1216–1231.

61.Singh B. N., Singh S. N., Reda D. J., et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352: 1861–1872.

62.Hughes M., Lip G. Y. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295–304.

63.Stroke in AF working group. Independent predictors of stroke in

patients with atrial fibrillation: a systematic review. Neurology 2007; 69: 546–554.

64. Schmitt J., Duray G., Gersh B. J., Hohnloser S. H. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009; 30: 1038–1045.

65.Gage B. F., Waterman A. D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864–2870.

66.Lip G. Y. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. J Thromb Haemost 2011; 9 (Suppl 1):344–351.

67.Gage B. F., Waterman A. D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864–2870.

68.Karthikeyan G., Eikelboom J. W.. The CHADS2 score for stroke risk stratification in atrial fibrillation – friend or foe? Thromb Haemost 2010;104:45–48.

69.Keogh C., Wallace E., Dillon C., et al. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost 2011; 106: 528–538.

70.Lin L. Y., Lee C. H., Yu C. C., et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation – a nationwide database analysis. Atherosclerosis 2011; 217: 292–295.

71.Olesen J. B., Fauchier L., Lane D. A., et al. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2012;

141:147–153.

72.Olesen J. B., Lip G. Y., Lane D. A., et al. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Am J Med 2012;

125:826.e13–23.

73.van Walraven C., Hart R. G., Connolly S., et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation. Stroke 2009;

40:1410–1416.

74.Olesen J. B., Lip G. Y., Hansen M. L., et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. Br Med J 2011; 342.

75.Potpara T. S., Polovina M. M., Licina M. M., et al. Reliable identification of “truly low” thromboembolic risk in patients initially diagnosed with “lone” atrial fibrillation: the Belgrade Atrial Fibrillation Study. Circ Arrhythm Electrophysiol 2012; 5: 319–326.

76.Olesen J. B., Torp-Pedersen C., Hansen M. L., Lip G. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: a nationwide cohort study. Thromb Haemost 2012; 107: 1172–1179.

77.Lip G. Y., Nieuwlaat R., Pisters R., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137: 263–272.

78.Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007; 69: 546–554.

79.Hughes M., Lip G. Y. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295–304.

80.Friberg L., Rosenqvist M., Lip G. Y. Evaluation of risk stratification schemes for is-chaemic stroke and bleeding in 182678 patients with atrial fibrillation: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2012; 33: 1500–1510.

81.AF-Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998; 158: 1316–1320.

82.Banerjee A., Taillandier S., Olesen J. B., et al. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. Eur J Heart Fail 2012;14: 295–301.

83.Friberg L., Benson L., Rosenqvist M., Lip G. Y. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ 2012; 344: e3522.

84.Avgil Tsadok M., Jackevicius C. A., Rahme E., et al. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA 2012; 307: 1952–1958.

85.Olesen J. B., Fauchier L., Lane D. A., et al.. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2012; 141: 147–153.

86.Potpara T. S., Polovina M. M., Licina M. M., et al. Reliable identification of “truly low” thromboembolic risk in patients initially diagnosed with “lone” atrial fibrillation: the Belgrade Atrial Fibrillation Study. Circ Arrhythm Electrophysiol 2012; 5: 319–326.

87.Olesen J. B., Torp-Pedersen C., Hansen M. L., Lip G. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: a nationwide cohort study. Thromb Haemost 2012; 107: 1172–1179.

88.Van Staa T. P., Setakis E., Di Tanna G. L., et al. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost 2011; 9: 39–48.

and validity of four contemporary risk stratification schemes to predict thromboembolism in non-anticoagulated patients with atrial fibrillation. Int J Cardiol. Published online ahead of print 19 November 2011.

90.Boriani G., Botto G. L., Padeletti L., et al. Italian AT-500 Registry Investigators. Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke 2011; 42: 1768–1770.

91.Lip G. Y., Nieuwlaat R., Pisters R., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137: 263–272.

92.Chao T. F., Lin Y. J., Tsao H. M., et al. CHADS (2) and CHA (2) DS (2) -VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. JACCl 2011; 58: 2380–2385.

93.Marinigh R., Lane D. A., Lip G. Y. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. JACC 2011; 57: 1339–1348.

94.Hart R. G., Pearce L. A., Aguilar M. I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857–867.

95.Sato H., Ishikawa K., Kitabatake A., et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006; 37: 447–451.

96.Mant J., Hobbs F. D., Fletcher K., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493–503.

97.Rash A., Downes T., Portner R., et al. A randomised controlled trial of warfarin vs. aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007; 36: 151–156.

98.Connolly S. J., Pogue J., Hart R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903–1912.

99.Connolly S. J., Pogue J, Hart R. G., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066–2078.

100.Lip G. Y. The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol 2011; 8: 602–606.

101.Olesen J. B., Lip G. Y., Lindhardsen J., et al. Risks of thrombo-

embolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a “real world” nationwide cohort study. Thromb Haemost 2011; 106: 739–749.

102. Ogilvie I. M., Welner S. A., Cowell W., Lip G. Y. Ischaemic stroke and bleeding rates in “real-world” atrial fibrillation patients. Thromb Haemost 2011; 106: 34–44.

103.Connolly S. J., Eikelboom J., Joyner C., et al.; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–817.

104.Connolly S. J., Pogue J., Hart R. G., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066–2078.

105.Seshasai S. R., Wijesuriya S., Sivakumaran R., et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172: 209–216.

106.Ahrens I., Lip G. Y., Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49–60.

107.Ruff C. T., Giugliano R. P., Antman E. M., et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial FibrillationThrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010; 160: 635–641.

108.Connolly S. J., Ezekowitz M. D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.

109.Connolly S. J., Ezekowitz M. D., Yusuf S., et al., for the Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly Identified Events in the RE-LY Trial. N Engl J Med 2010; 363: 1875–1876.

110.Hohnloser S. H., Oldgren J., Yang S., et al. Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. Circulation 2012; 125: 669–676.

111.Ezekowitz M. D., Walentine L., Connolly S., et al. Dabigatran and Warfarin in vitamin K antagonist-naïve and –experienced cohorts with atrial fibrillation. Circulation 2010: 122: 2246–2253.

112.Wallentin L., Yusuf S., Ezekowitz M. D., et al. Efficasy and Safety of Dabigatran compared with Warfarin at different levels of INR control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975–983.

113.Nagaracanti R., Ezekowitz M. D., Oldgren J., et al. Dabigatran versus Warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 131–136.

114.Diener H. C., Connolly S., Ezekowitz M. D., et al. Efficasy and Safety of Dabigatran compared with Warfarin Dabigatran in patients with atrial fibrillation and previous transient ischaemic attack or stroke:

a subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9: 1157–1163.

115.Huisman M. V., Lip G., Diener H. – C., et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertaines in routine practice. Thromb Haemost 2012; 107: Doi:10.1160/TH11–10–0718.

116.Lip G. Y.H., Larsen T. B., Skjoth F., Rasmussen L. H. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. JACC 2012; 60: 738–746.

117.De Caterina R., Husted S., Wallentin L., et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease position paper. JACC 2012; 59:1413–1425.

118.Freeman J. V., Zhu R. P., Owens D. K., et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011; 154: 1–11.

119.Sorensen S. V., Kansal A. R., Connolly S., et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011; 105: 908–919.

120.Pink J., Lane S., Pirmohamed M., Hughes D. A. Dabigatran etexilate vs. warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ 2011; 343: d6333.

121.Shah S. V., Gage B. F. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011; 123: 2562–2570.

122.Banerjee A., Lane D. A., Torp-Pedersen C., Lip G. Y. Net clinical benefit

of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs. no treatment in a “real world” atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584–589.

123.Douxfils J., Mullier F., Robert S., et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985–997.

124.van Ryn J., Stangier J., Haertter S., et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116–1127.

125.Tripodi A. Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test? Thromb Haemost 2011; 105:735–736.

126.Barrett Y. C., Wang Z., Frost C., Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263–1271.

127.Pengo V., Crippa L., Falanga A., et al.; Italian Federation of Thrombosis Centers. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011; 106: 868–876.

128.Eerenberg E. S., Kamphuisen P. W., Sijpkens M. K., et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573–1579.

129.Marlu R., Hodaj E., Paris A., et al. Effect of nonspecific reversal agents on anticoagulant activity of dabigatran, rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217–224.

130.Sie P., Samama C. M., Godier A., et al.; Working Group on Perioperative Haemostasis; French Study Group on Thrombosis and Haemostasis. Surgery and invasive procedures in patients on longterm treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis 2011; 104: 669–676.

131.Omran H., Bauersachs R., Rubenacker S., Goss F., Hammerstingl C. The HAS-BLED score predicts bleedings during

bridging of chronic oral anticoagula-tion. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost 2012; 108: 65–73.

132.Winkle R. A., Mead R. H., Engel G., et al. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2011; 23: 264–268.

133.Lakkireddy D., Reddy Y. M., Di Biase L., et al. Feasibility and safety of dabigatran vs. warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial Fibrillation results from a multicenter prospective registry. JACC 2012; 59: 1168–1174.

134.Eikelboom J. W., Wallentin L., Connolly S. J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363–2372.

135.Ruiz-Nodar JM, Marın F., Roldan V., et al. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stent-ing with a high HAS-BLED bleeding risk score? Circ Cardiovasc Interv 2012: 5: 459–466.

136.Lip G. Y., Huber K., Andreotti F., et al.; Consensus Document of European Society of Cardiology Working Group on Thrombosis. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting. Eur Heart J 2010; 31: 1311–1318.

137.Huber K., Airaksinen K. J., Cuisset T., et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106: 569–571.

138.Faxon D. P., Eikelboom J. W., Berger P. B., et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 572–584.

139.Mega J. L., Braunwald E., Wiviott S. D., et al.; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9–19.

140.Alexander J. H., Lopes R. D., James S., et al.; APPRAISE-2 Investigators. Apixaban with antiplate-let therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699–708.

141.Matute M. C., Masjuan J., Egido J. A., et al. Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants. Cerebrovasc Dis 2012; 33: 231–239.

142.Connolly S. J., Pogue J., Eikelboom J., Flaker G., et al.; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy

in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029–2037.

143. Gallagher A. M., Setakis E., Plumb J. M., et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106: 968–977.

144.Morgan C. L., McEwan P., Tukiendorf A., et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 2009; 124: 37–41.

145.Connolly S. J., Eikelboom J. W., Ng J., et al.; ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbe-sartan for Prevention of Vascular Events) Steering Committee and Investigators. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med 2011;

155:579–586.

146.Lip G. Y., Andreotti F., Fauchier L., et al. Bleeding risk assessment,

management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Europace 2011; 13: 723–746.

147.Gage B. F., Yan Y., Milligan P. E., et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713–719.

148.Pisters R., Lane D. A., Nieuwlaat R., et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with

atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093– 1100.

149.Fang M. C., Go A. S., Chang Y., et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Antic-oagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011;58: 395–401.

150.Roldan V., Marin F., Manzaro-Fernandez S., et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real world” anticoagulated atrial fibrillation population. Chest. Published online ahead of print 21 June 2012. http://dx.doi. org/10.1378/chest.12–0608-doi:10.1378/ chest.12–0608.

151.Apostolakis S., Lane D. A., Guo Y., et al. Performance of the HEMORR2HAGES, ATRIA and HAS-BLED bleeding risk prediction scores in anticoagulated patients with atrial fibrillation: The AMADEUS study. JACC 2012: 60: 861–867.

152.Lip G. Y., Frison L., Halperin J. L., Lane D. A. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly) score. JACC 2011; 57: 173–180.

153.Olesen J. B., Lip G. Y., Hansen P. R., et al. Bleeding risk in “real world” patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost 2011; 9: 1460–1467.

154.Gallego P., Roldan V., Torregrosa J. M., et al. Relation of the HASBLED bleeding risk score to major bleeding, cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2012: 5: 312–318.

155.Lane D. A., Lip G. Y.H. Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in non-valvular atrial fibrillation. Circulation 2012: 126: 860–865.

156.Friberg L., Rosenqvist M., Lip G. Net clinical benefit of warfarin in patients with atrial fibrillation: A report from the Swedish Atrial Fibrillation cohort study. Circulation 2012; 125: 2298–2307.

157.Hansen M. L., Sørensen R., Clausen M. T., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170: 1433– 1441.

158.Zhao H. – J., Zheng Z-T., Wang Z. – H., et al. “Triple Therapy” Rather Than “Triple Threat”. A Meta-analysis of the Two Antithrombotic Regimens After Stent Implantation in Patients Receiving Long-term Oral Anticoagulant Treatment. Chest 2011; 139: 260–270.

159.Murray R. D., Deitcher S. R., Shah A., et al. Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low- molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation. J Am Soc Echocardiogr 2001; 14: 200–208.

160.Stellbrink C., Nixdorff U., Hofmann T., et al.; on Behalf of the ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group. Safety and Efficacy of Enoxaparin Compared With Unfractionated Heparin and Oral Anticoagulants for Prevention of Thromboembolic Complications in Cardioversion of Nonvalvular Atrial Fibrillation. The Anticoagulation in Cardioversion using Enoxaparin (ACE) Trial. Сirculation 2004; 109: 997–1003.

161.Potpara T. S., Polovina M. M., Licina M. M., et al. Reliable identification of “truly low” thromboembolic risk in patients initially diagnosed with “lone” atrial fibrillation: The Belgrade Atrial Fibrillation Study. Circ Arrhythm Electrophysiol 2012; 5: 319–326.

162.Singer D. E., Chang Y., Fang M. C., et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297–305.

163.De Caterina R., Connolly S. J., Pogue J., et al. Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. Eur Heart J 2010; 31: 2133–2140.

164.Hylek E. M., D’Antonio J., Evans-Molina C., et al. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006;37: 1075–1080.

165.Fox K. A., Piccini J. P., Wojdyla D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387–2394.

166.Wilke T., Groth A., Mueller S., et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012; 107: 1053–1065.

167.van Walraven C., Hart R. G., Connolly S., et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation. Stroke 2009; 40: 1410–1416.

168.Corley S. D., Epstein A. E., DiMarco J.P., et al.; AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109: 1509–1513.

169.Singer D. E., Albers G. W., Dalen J. E., et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 546S–592S.

170.Klein A. L., Grimm R. A., Murray R. D., et al.; Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344: 1411–1420.

171.Cox J. L. Cardiac surgery for arrhythmias. J Cardiovasc Electrophysiol 2004;15: 250–262.

172. Bayard Y. L., Omran H., Neuzil P., et al. PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. EuroIntervention 2010; 6: 220–226.

173.Park J. W., Bethencourt A., Sievert H., et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv 2011; 77: 700–706.

174.Holmes D. R., Reddy V. Y., Turi Z. G., et al. Percutaneous closure of the left atrial appendage vs. warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374: 534–542.

175.Whitlock R. P., Healey J. S., Connolly S. J. Left atrial appendage occlusion does not eliminate the need for warfarin. Circulation 2009; 120: 1927–1932; discussion 32.

176.Dawson A. G., Asopa S., Dunning J. Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion? Interact Cardiovasc Thorac Surg 2010; 10: 306–311.

177.Reddy V. Y., Holmes D., Doshi S. K., et al. Safety of percutaneous left atrial appendage closure: results from the Watchman left

Circulation 2011; 123: 417–424.

178.Poldermans D., Bax J. J., Boersma E., et al. Guidelines for preoperative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol 2010; 27: 92–137.

179.Alboni P., Botto G. L., Baldi N., et al. Outpatient treatment of recentonset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med 2004; 351: 2384–2391.

180.Kowey P. R., Dorian P., Mitchell L. B., et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009; 2: 652–659.

181.Roy D., Pratt C. M., Torp-Pedersen C., et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008; 117: 1518–1525.

182.Camm A. J., Capucci A., Hohnloser S., et al. A randomized activecontrolled study comparing the efficacy and safety of vernakalant to amiodarone in recent onset atrial fibrillation. JACC 2010; in press.

183.Сулимов В. А., Гиляров. М. Ю. Применение нового отчественного антиаритмического препарата III класса нибентана для устранения пароксизмальной формы фибрилляции предсердий. Российский кардиологический журнал 2002: № 6: 49–55.

184.Шубик Ю. В., Медведев М. М., Ривин А. Е. Нибентан: препарат для фармакологической кардиоверсии при персистирующей форме фибрилляции предсердий. Кардиология 2005; № 2: 19–24.

185.Попов С. В., Аубакирова Г. А., Антонченко И. В. и др. Эффективность антиаритмического препарата III класса нибентана у больных с фибрилляцией предсердий. Вестник аритмологии

2003; 31: 10–14.

186.БрегвадзеИ. Н., МайковЕ. Б., БильдиновО. А. идр. Эффективность

ибезопасность нибентана при медикаментозной кардиоверсии у больных с персистирующей формой фибрилляции предсердий: роль ограничения доз препарата и применения магния сульфата.

Кардиология 2007; 3: 48–55.

187.Halpern S. W., Ellroot G., Singh B. N., Mandel W. J. Efficacy of intravenous procainamid infusion in converting atrial fibrillation to sinus rhythm. Relation to left atrium size. Brit Heart J 1980; 44: 589–595.

188.Fenster P. E., Comess K. A., Marsh A., et al. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J 1983; 106: 501–504.

189.Kochiadakis G. E., Igoumenidis N. E., Solomou M. C., et al. Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion. Cardiovasc Drugs Ther 1998; 12: 75–81.

190.Kochiadakis G. E., Igoumenidis N. E., Hamilos M. E., et al. A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation. Am J Cardiol 2007; 99: 1721–1725.

191.Stiell I. G., Clement C. M., Symington C., et al. Emergency department use of intravenous procainamide for patients with acute atrial fibrillation or flutter. Acad Emerg Med 2007; 14: 1158–1164.

192.Чазов Е. И., Голицын С. П. Руководство по нарушениям ритма сердца. ГЭОТАР-Медиа, 2008.

193.Reisinger J., Gatterer E., Lang W., et al. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J 2004; 25: 1318–1324.

194.Khan I. A. Single oral loading dose of propafenone for pharmacological cardiover-sion of recent-onset atrial fibrillation. JACC 2001; 37: 542–547.

195.Martinez-Marcos F.J., Garcia-Garmendia J.L., Ortega-Carpio A., et al. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000; 86: 950–953.

196.Chevalier P., Durand-Dubief A., Burri H., et al. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. JACC 2003; 41: 255–262.

197.Vardas P. E., Kochiadakis G. E., Igoumenidis N. E., et al. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest 2000; 117: 1538–1545.

198.Bianconi L., Castro A., Dinelli M., et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, doubleblind, placebo-controlled study. Eur Heart J 2000; 21: 1265–1273.

199.Stambler B. S., Wood M. A., Ellenbogen K. A. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Circulation 1997; 96: 4298–4306.

200.Востриков В. А. Эффективность и безопасность электроимпульсной терапии фибрилляции предсердий. В кн.: Методы нелинейного анализа в кардиологии и онкологии. Под редакцией Р. З. Назирова. Из-во Университет книжный дом, 2010, стр. 73–79.

201.Kirchhof P., Eckardt L., Loh P., et al. Anterior–posterior versus anterior–lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet 2002; 360: 1275–1279.

202.Oral H., Souza J. J., Michaud G. F., et al. Facilitating transthoracic

cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999; 340: 1849–1854.

203.Manios E. G., Mavrakis H. E., Kanoupakis E. M., et al. Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study. Cardiovasc Drugs Ther 2003; 17: 31–39.

204.Bianconi L., Mennuni M., Lukic V., et al. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. JACC 1996; 28: 700–706.

205.Roy D., Talajic M., Dorian P. et al. Amiodaron to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342: 913–920.

206.Кадырова М. М. Автореферат диссертации на соискание ученой степени кандидата медицинских наук “Антиаритмические и гемодинамические эффекты аллапинина у больных с мерцательной аритмией до и после восстановления синусового ритма в сравнении с хинидином бисульфатом”. Москва, 1990.

207.Бунин Ю. А., Фирстова М. И., Енукашвили Р. Р. Поддерживающая антиаритмическая терапия после восстановления синусового ритма у больных с постоянной формой мерцательной аритмии.

Материалы 5-го Всероссийского съезда кардиологов. Челябинск, 1996: 28.

208. Gulamhusein S., Ko P., Carruthers S. G., Klein G. J. Acceleration of the ventricular response during atrial fibrillation in the Wolff– Parkinson–White syndrome after verapamil. Circulation 1982; 65: 348–354.

209.Fetsch T., Bauer P., Engberding R., et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004; 25: 1385–1394.

210.Cosio F. G., Aliot E., Botto G. L., et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace 2008; 10: 21–27.

211.Kirchhof P. Can we improve outcomes in atrial fibrillation patients by early therapy? BMC Med 2009; 7: 72.

212.AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825–1833.

213.Van Gelder I. C., Hagens V. E., Bosker H. A., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834–1840.

214.Carlsson J., Miketic S., Windeler J., et al., and the STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation. J Am Coll Cardiol 2003; 41: 1690–1696.

215.Opolski G., Torbicki A., Kosior D. A., et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004; 126: 476–486.

216.Roy D., Talajic M., Nattel S., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667–2677.

217.Ogawa S., Yamashita T., Yamazaki T., et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J 2009; 73: 242–248.

218.Hohnloser S. H., Kuck K. H., Lilienthal J. Rhythm or rate control in atrial fibrilla-tion – Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356: 1789–1794.

219.Hsu L. F., Jais P., Sanders P., et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004; 351: 2373–2383.

220.Khan M. N., Jais P., Cummings J., et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008; 359: 1778–1785.

221.Hohnloser S. H., Crijns H. J., van Eickels M., et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668–678.

222.Wilber D. J., Pappone C., Neuzil P., et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010; 303: 333–340.

223.Talajic M., Khairy P., Levesque S., et al. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. JACC 2010; 55: 1796–1802.

224.Van Gelder I. C., Groenveld H. F., Crijns H. J., et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363–1373.

225.Singh B. N., Connolly S. J., Crijns H. J., et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357: 987–999.

226.Segal J. B., McNamara R.L., Miller M. R., et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract 2000; 49: 47–59.

227.Hou Z. Y., Chang M. S., Chen C. Y., et al. Acute treatment of recentonset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J 1995; 16: 521–528.

228.Redfearn D. P., Krahn A. D., Skanes A. C., et al. Use of medications in Wolff–Parkinson–White syndrome. Expert Opin Pharmacother 2005;

6:955–963.

229.Davy J. M., Herold M., Hoglund C., et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008; 156: 527.e1–527.e9.

230.Murgatroyd F. D., Gibson S. M., Baiyan X., et al. Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation. Circulation 1999; 99: 2765–2770.

231.Gasparini M., Auricchio A., Metra M., et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J 2008; 29: 1644–1652.

232.Ozcan C., Jahangir A., Friedman P. A., et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 2001; 344: 1043–1051.

233.Weerasooriya R., Davis M., Powell A., et al. The Australian intervention randomized control of rate in atrial fibrillation trial (AIRCRAFT). JACC 2003; 41: 1697–1702.

234.Upadhyay G. A., Choudhry N. K., Auricchio A., et al. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. JACC 2008; 52: 1239–1246.

235.Auricchio A., Metra M., Gasparini M., et al. Long-term survival of patients with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy. Am J Cardiol 2007; 99: 232–238.

236.Dong K., Shen W. K., Powell B. D., et al. Atrioventricular nodal ablation predicts survival benefit in patients with atrial fibrillation receiving cardiac resynchronization therapy. Heart Rhythm 2010; Feb 17 [Epub ahead of print].

237.Kirchhof P., Andresen D., Bosch R., et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 2012; 380: 238–246.

238.Ahmed S., Rienstra M., Crijns H. J., et al.; CONVERT Investigators. Continuous vs. episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA 2008;

300:1784–1792.

239.Connolly S. J. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999; 100: 2025–2034.

240. Lafuente-Lafuente C., Mouly S., Longas-Tejero M.A., Bergmann J. F. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2007;

4: CD005049.

241.McNamara R.L., Bass E. B., Miller M. R., et al. Management of new onset atrial fibrillation (evidence report/Technology assessment). In: Agency for Heathcare Research and Quality. 2001, Publication No. AHRQ 01-E026.

242.Соколов С. Ф., Джагангиров Ф. Н. Антиаритмический препарат аллапинин: обзор результатов клинического изучения.

Кардиология 2002; № 7: 96–102.